|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Daily dosing of either non-steroidal anti-inflammatory drugs (NSAIDs) or EGFR inhibitors has been shown to prevent bladder cancer development in a N-butyl-(4-hydroxybutyl)nitrosamine (OH-BBN) induced rat model.
|
31818850 |
2020 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, it is reported that epidermal growth factor receptor ligands induced by the upregulation of vascular endothelial growth factor (VEGF)‑A and VEGF‑C via the VEGF receptor (R)2/nuclear factor‑κB signaling pathway in ECs, may trigger EGFR signaling in bladder cancer cells and promote bladder cancer progression.
|
30816487 |
2019 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, TRIP13 expression was positively correlated with EGFR expression in BCa specimens, and the high expression of both TRIP13 and EGFR predicted poor survival.
|
31337978 |
2019 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
These UCNP-AuNR nanoclusters are further functionalized with antibodies to epidermal growth factor receptor (EGFR) to target bladder cancer cells known to overexpress EGFRs.
|
30678969 |
2019 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Epidermal Growth Factor Receptor-Targeted Multifunctional Photosensitizers for Bladder Cancer Imaging and Photodynamic Therapy.
|
30776232 |
2019 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ERα decreased circ_0023642 levels and subsequently increased miR-490-5p expression, resulting in decreased EGFR expression to suppress BCa cell invasion.
|
31455760 |
2019 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
About 45% of BC tissues stain for both EGFR and HER2.
|
30765854 |
2019 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
The cytotoxicity of <sup>111</sup>In delivered by the EGFR-targeted MNT (<sup>111</sup>In-MNT) was greatly enhanced on EJ-, HT-1376-, and 5637-expressing EGFR bladder cancer cell lines compared with <sup>111</sup>In non-targeted control.
|
30510514 |
2018 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phenformin alone or combined with gefitinib inhibits bladder cancer via AMPK and EGFR pathways.
|
30053908 |
2018 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, we aimed to investigate whether EGFR or HER2 may serve as a target for T cell-mediated immunotherapy against human bladder cancer.
|
29328392 |
2018 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We aimed to investigate the prognostic significance of EGFR expression in patients receiving cisplatin-based adjuvant chemotherapy following radical cystectomy for advanced BC.
|
30413194 |
2018 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Exploring the roles of urinary HAI-1, EpCAM & EGFR in bladder cancer prognosis & risk stratification.
|
29861867 |
2018 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Epidermal growth factor receptor (EGFr)-targeted therapy may be used in subgroups of patients with urinary bladder cancer.
|
29508172 |
2018 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Epidermal Growth Factor Receptor Family Inhibition Identifies P38 Mitogen-activated Protein Kinase as a Potential Therapeutic Target in Bladder Cancer.
|
29154981 |
2018 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, miR-202 suppresses bladder cancer carcinogenesis and progression by targeting EGFR, thereby representing a potential target for miRNA-based therapy for bladder cancer in the future.
|
29298735 |
2018 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
The p53 and EGFR pathways are frequently altered in bladder cancer, yet their contributions to its progression remain elusive.
|
29440146 |
2018 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
EGFR expression was confirmed to be elevated in six bladder cancer cell lines.
|
29456764 |
2018 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, a mutation panel of six cancer-associated genes (TSC1, FGFR3, TERT, TP53, PIK3CA and ERBB2) and an immunohistochemistry (IHC) panel containing eight bladder cancer (BC) biomarkers (EGFR, RRM1, PD-L1, BRCA1, TUBB3, ERCC, ERCC1, aberrantly glycosylated integrin α3β1 (AG) and CK5/6) were developed.
|
29941343 |
2018 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that high sHER3 levels are associated with improved survival rates in patients with bladder cancer, and that sHER3 inhibits bladder cancer cell growth and migration.
|
29434875 |
2018 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overexpression of Epidermal Growth Factor Receptor (EGFR) and HER-2 in Bladder Carcinoma and Its Association with Patients' Clinical Features.
|
30296252 |
2018 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Significant association of EGFR overexpression with tumor grade, muscularis propria invasion and recurrence signifies its prognostic value; therefore EGFR can be used as a prognostic biomarker in Urothelial bladder carcinoma.
|
29879970 |
2018 |
|
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A total, 50 Moroccan patient specimens with bladder cancer and 48 healthy controls were analysed for EGFR mutations in the region delimiting exons 18-21 by PCR amplification and direct sequencing.
|
28719349 |
2017 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Bladder cancer tissue microarray (TMA) and bladder cancer cell lines were analyzed for expression of EGFR.
|
28619755 |
2017 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
XIAP BIR domain suppresses miR-200a expression and subsequently promotes EGFR protein translation and anchorage-independent growth of bladder cancer cell.
|
28057023 |
2017 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The epidermal growth factor receptor (EGFR) family is reportedly overexpressed in bladder cancer, and tyrosine kinase inhibitors (TKIs) have been suggested as treatment.
|
25482142 |
2015 |